5.05
-0.01 (-0.20%)
| Penutupan Terdahulu | 5.06 |
| Buka | 5.08 |
| Jumlah Dagangan | 3,003,478 |
| Purata Dagangan (3B) | 6,279,946 |
| Modal Pasaran | 1,383,292,800 |
| Harga / Jualan (P/S) | 191.40 |
| Harga / Buku (P/B) | 5.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -930.54% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -32.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 111.93% |
| Nisbah Semasa (MRQ) | 5.35 |
| Aliran Tunai Operasi (OCF TTM) | -83.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.28 M |
| Pulangan Atas Aset (ROA TTM) | -35.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -159.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Taysha Gene Therapies, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.20 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.11% |
| % Dimiliki oleh Institusi | 67.23% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (Raymond James, 157.43%) | Beli |
| Median | 12.00 (137.62%) | |
| Rendah | 8.00 (Citizens, 58.42%) | Beli |
| Purata | 11.00 (117.82%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 4.56 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 05 Nov 2025 | 12.00 (137.62%) | Beli | 4.03 |
| 17 Oct 2025 | 12.00 (137.62%) | Beli | 4.72 | |
| Citizens | 05 Nov 2025 | 8.00 (58.42%) | Beli | 4.03 |
| Raymond James | 21 Oct 2025 | 13.00 (157.43%) | Beli | 5.15 |
| Needham | 17 Oct 2025 | 10.00 (98.02%) | Beli | 4.72 |
| 02 Oct 2025 | 10.00 (98.02%) | Beli | 4.88 | |
| Baird | 02 Oct 2025 | 12.00 (137.62%) | Beli | 4.88 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| NAGENDRAN SUKUMAR | - | 4.59 | -370,172 | -1,674,001 |
| Jumlah Keseluruhan Kuantiti Bersih | -370,172 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,674,001 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 4.59 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| NAGENDRAN SUKUMAR | Pegawai | 01 Dec 2025 | Jual (-) | 260,047 | 4.43 | 1,152,008 |
| NAGENDRAN SUKUMAR | Pegawai | 01 Dec 2025 | Pelaksanaan pilihan | 260,047 | - | - |
| NAGENDRAN SUKUMAR | Pegawai | 28 Nov 2025 | Jual (-) | 110,125 | 4.74 | 521,993 |
| NAGENDRAN SUKUMAR | Pegawai | 28 Nov 2025 | Pelaksanaan pilihan | 110,125 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |